|
|
|
|
Research and Markets: Cubist Pharmaceuticals, Inc. - SWOT Analysis: The Essential Source For Top-Level Company Data and Information
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/f45686/cubist_pharmaceuti) has announced the addition of the "Cubist Pharmaceuticals, Inc.- SWOT Analysis" company profile to their offering. Cubist Pharmaceuticals,...
|
|
|
Research and Markets: Cubist Pharmaceuticals, Inc. - SWOT Analysis: The Essential Source For Top-Level Company Data and Information
DUBLIN-- (BUSINESS WIRE) -- Research and Markets (http://www.researchandmarkets.com/research/f45686/cubist_pharmaceuti) has announced the addition of the "" company profile to their offering.company profile is the essential source for top-level company data...
|
|
|
Research and Markets: Cubist Pharmaceuticals, Inc. - SWOT Analysis: The Essential Source For Top-Level Company
Companies mentioned in this article: Research and Markets DUBLIN -- (BUSINESS WIRE) -- Research and Markets (http://www.researchandmarkets.com/research/f45686/cubist_pharmaceuti) has announced the addition of the 'Cubist Pharmaceuticals, Inc.- SWOT Analysis'...
|
|
|
Research and Markets: Cubist Pharmaceuticals, Inc. - SWOT Analysis: The Essential Source For Top-Level Company Data and Information ..
Research and Markets ( www.researchandmarkets.com/research/f45686/cubist_pharmaceuti : ) has announced the addition of the " Cubist Pharmaceuticals, Inc.- SWOT Analysis : " company profile to their offering. Cubist Pharmaceuticals, Inc. - SWOT Analysis :...
|
|
|
Research and Markets: Cubist Pharmaceuticals, Inc. - SWOT Analysis: The Essential Source For Top-Level Company Data and
Research and Markets: : The Essential Source For Top-Level Company Data and Information DUBLIN - (BUSINESS WIRE) - Research and Markets (http://www.researchandmarkets.com/research/f45686/cubist_pharmaceuti) has announced the addition of the "" company profile...
|
|
|
Research and Markets: Cubist Pharmaceuticals, Inc. - SWOT Analysis: The Essential Source For Top-Level Company
Research and Markets (http://www.researchandmarkets.com/research/f45686/cubist_pharmaceuti) has announced the addition of the 'Cubist Pharmaceuticals, Inc.- SWOT Analysis' company profile to their offering. Cubist Pharmaceuticals, Inc. - SWOT Analysis...
|
|
|
Research and Markets: Cubist Pharmaceuticals, Inc. - SWOT Analysis: The Essential Source For Top-Level Company
Research and Markets: : The Essential Source For Top-Level Company Data and Information DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/f45686/cubist_pharmaceuti) has announced the addition of the '' company profile to...
|
|
|
Research and Markets: Cubist Pharmaceuticals, Inc. - SWOT Analysis: The Essential Source For Top-Level Company Data And Informat
Research and Markets (http://www.researchandmarkets.com/research/2cb792/cubist_pharmaceuti) has announced the addition of the "Cubist Pharmaceuticals, Inc.- SWOT Analysis" company profile to their offering. Cubist Pharmaceuticals, Inc. - SWOT Analysis...
|
|
|
Cubist Pharmaceuticals, Inc. (CBST) (JOBS) Maintains Growth Streak, As Investors Fear Generic Threat, Thin Pip
Xconomy.com -- Cubist Pharmaceuticals has grown into one of the big success stories in biotech industry of the past few years, based almost entirely on the sales of a single product.The Lexington, MA-based companys big hit is an intravenous antibiotic for...
|
|
|
Cubist Pharmaceuticals Announces Full Year 2009 Total Net Revenues of $562.1 Million
GAAP DILUTED NET INCOME OF $0.38 PER SHARE IN FOURTH QUARTER GAAP DILUTED NET INCOME OF $1.36 PER SHARE FOR FULL YEAR NON-GAAP DILUTED NET INCOME OF $2.29 PER SHARE FOR FULL YEAR LEXINGTON, MA, USA I January 21, 2010 I Cubist Pharmaceuticals, Inc.(NASDAQ:...
|
|
|
Cubist Pharmaceuticals, Inc. (CBST) Maintains Growth Streak, As Investors Fear Generic Threat, Thin Pipeline
Xconomy.com -- Cubist Pharmaceuticals has grown into one of the big success stories in biotech industry of the past few years, based almost entirely on the sales of a single product.The Lexington, MA-based companys big hit is an intravenous antibiotic for...
|
|
|
Cubist Pharmaceuticals 4Q Profit Tumbles 76%
LEXINGTON, Mass.(AP) ' Cubist Pharmaceuticals Inc. reported Thursday that its fourth-quarter profit dropped 76 percent from a year-ago period helped by a hefty tax benefit, but said sales of its antibiotic Cubicin sharply increased. The company...
|
|
|
Cubist Pharma profit fell 76 percent, but sales of Cubicin rose 23 percent in 4th quarter
LEXINGTON, MASS.Cubist Pharmaceuticals Inc. reported Thursday that its fourth-quarter profit dropped 76 percent from a year-ago period helped by a hefty tax benefit, but said sales of its antibiotic Cubicin sharply increased. The company said its...
|
|
|
Cubist Pharmaceuticals, Inc. Q4 2009 Earnings Call Transcript
Cubist Pharmaceuticals, Inc.(CBST) Executives Eileen McIntyre Senior Director, Corporate Communications David McGirr SVP & CFO Rob Perez EVP & COO Steve Gilman SVP, Discovery & Nonclinical Development and Chief Scientific Officer Mike Bonney...
|
|
|
Cubist Pharmaceuticals Announces Full Year 2009 Total Net Revenues of $562.1 Million
GAAP DILUTED NET INCOME OF $0.38 PER SHARE IN FOURTH QUARTER GAAP DILUTED NET INCOME OF $1.36 PER SHARE FOR FULL YEAR NON-GAAP DILUTED NET INCOME OF $2.29 PER SHARE FOR FULL YEAR LEXINGTON, Mass.-- (BUSINESS WIRE) -- Cubist Pharmaceuticals, Inc.(NASDAQ: CBST...
|
|
|
Cubist Pharmaceuticals Announces Full Year 2009 Total Net Revenues of $562.1 Million
GAAP DILUTED NET INCOME OF $0.38 PER SHARE IN FOURTH QUARTER GAAP DILUTED NET INCOME OF $1.36 PER SHARE FOR FULL YEAR NON-GAAP DILUTED NET INCOME OF $2.29 PER SHARE FOR FULL YEAR LEXINGTON, Mass.--(EON: Enhanced Online News)--Cubist Pharmaceuticals, Inc....
|
|
|
Cubist Pharmaceuticals Announces Full Year 2009 Total Net Revenues of $562.1 Million
LEXINGTON, Mass.-- (NASDAQ: CBST) today announced results for the fourth quarter and year ended December 31, 2009. Cubist acquired Calixa Therapeutics Inc. in December Operating income grew 52% over 2008 Total net revenues for 2009 increased 30% over...
|
|
|
Cubist Pharmaceuticals Announces Full Year 2009 Total Net Revenues of $562.1 Million
GAAP DILUTED NET INCOME OF $0.38 PER SHARE IN FOURTH QUARTER GAAP DILUTED NET INCOME OF $1.36 PER SHARE FOR FULL YEAR NON-GAAP DILUTED NET INCOME OF $2.29 PER SHARE FOR FULL YEAR LEXINGTON, Mass.--(BUSINESS WIRE)-- (NASDAQ: CBST - News) today announced results...
|
|
|
Cubist Pharmaceuticals Announces Full Year 2009 Total Net Revenues of $562.1 Million
LEXINGTON, Mass.(Business Wire) -- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced results for the fourth quarter and year ended December 31, 2009. Cubist acquired Calixa Therapeutics Inc. in December Operating income grew 52% over 2008...
|
|
|
Cubist Pharma Q4 Profit Plunges - Update
1/21/2010 5:24 PM ET RELATED NEWS TOP MARKET NEWS (RTTNews) - Thursday, Cubist Pharmaceuticals, Inc.(CBST: News ) reported a sharp decline in fourth-quarter profit from the year ago due to the absence of a significant tax benefit which helped previous year's...
|
|
|
Cubist Pharmaceuticals Announces Full Year 2009 Total Net Revenues of $562.1 Million
--GAAP DILUTED NET INCOME OF $1.36 PER SHARE FOR FULL YEAR --NON-GAAP DILUTED NET INCOME OF $2.29 PER SHARE FOR FULL YEAR Cubist Pharmaceuticals, Inc.( NASDAQ:CBST) today announced results for the fourth quarter and year ended December 31, 2009. -- Cubist...
|
|
|
A Closer Look at Cubist Pharma
Scott Raynovich Send Message You are currently following R.Scott Raynovich Stop Following You are no longer following R. Scott Raynovich About this author: Visit: Rayno Report Submit an article to Font Size: Print Email Cubist Pharmaceuticals (CBST) is an...
|
|
|
Cubist Pharmaceuticals Announces Full Year 2009 Total Net Revenues of $562.1 Million
- (NASDAQ: CBST) today announced total revenues for both the fourth quarter and full year ended December 31, 2009.Fourth Quarter and Full Year Highlights: Full year 2009 U.S. CUBICIN (daptomycin for injection) net product revenues of $524.0 million...
|
|
|
Cubist Pharmaceuticals Releases 4Q and Full Year 2009 Results - Z...
Company: Cubist Pharmaceuticals, Inc.(CBST) Cubist Pharmaceuticals, Inc. has announced total revenues for both the fourth quarter and full year ended December 31. In a release on January 11, the Company noted that fourth quarter 2009 U.S. Cubicin...
|
|
|
Cubist Pharmaceuticals Releases 4Q and Full Year 2009 Results
Cubist Pharmaceuticals, Inc.has announced total revenues for both the fourth quarter and full year ended December 31. In a release on January 11, the Company noted that fourth quarter 2009 U.S. Cubicin net product revenues of $147.8 million ...
|
